Company Overview and News

2
Various Tailwinds Aid Allegiant (ALGT): Retain Stock for Now

2018-10-15 zacks
We have issued an updated research report on Allegiant Travel Company (ALGT - Free Report) on Oct 12.
ARCB TRN ALGT NSC

2
JetBlue's September Traffic Increases, Load Factor Down

2018-10-11 zacks - 1
JetBlue Airways Corporation (JBLU - Free Report) reported decent traffic figures for September 2018. Traffic (measured in revenue passenger miles or RPMs) improved 18.5% year over year to 3.9 billion. On a year-over-year basis, capacity (or available seat miles/ASMs) climbed 19.3% to 4.9 billion.
ARCB JBLU MATX NSC

 
Is Norfolk Southern (NSC) Stock Outpacing Its Transportation Peers This Year?

2018-10-09 zacks
For those looking to find strong Transportation stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Norfolk Southern (NSC - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Transportation peers, we might be able to answer that question.
NSC

2
Lazard Global Listed Infrastructure: A Solid Defensive Option

2018-10-08 seekingalpha - 1
As part of my research into Lazard (LAZ) I looked at Lazard Global Listed Infrastructure Portfolio Institutional Shares (GLIFX). A very nice find. Often the first thing I do is to look through a fund's portfolio to see what they own. The table below show this fund's largest positions:
EIX SIZAY NG LAZ RDEIF REE NGGTF CSX FPRUF NGG NSC

14
Top Stock Reports for Apple, Microsoft & Pfizer

2018-10-08 zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Microsoft (MSFT) and Pfizer (PFE). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
HAWLN HD LMT CAT HAWLM HAWLL UTX HAWEL NSC HAWEN HAWEM COP AAPL MSFT HAWLI PFE RPM CIT

7
Delta Air Lines' (DAL) Q3 Earnings: A Beat in the Offing?

2018-10-05 zacks
Delta Air Lines, Inc. (DAL - Free Report) is slated to release its third-quarter 2018 results, before the market opens on Oct 11.
UPS CSX DAL NSC YY

4
Why the Earnings Surprise Streak Could Continue for Norfolk Southern (NSC)

2018-10-05 zacks
Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Norfolk Southern (NSC - Free Report) , which belongs to the Zacks Transportation - Rail industry, could be a great candidate to consider.
NSC YY

 
Railroad Industry Outlook: Economy Boom to Retain the Upside

2018-10-04 zacks
Railroad fortunes are contingent on coal as revenues from the commodity contribute significantly to the respective companies’ top line. Despite President Donald Trump’s pro-coal stance, the industry does not seem to have revived much. U.S. coal production registered 180.8 million tons in the second quarter of 2018, down 3.7% sequentially and 3.4% year over year. This was reportedly the third straight quarter decline.
LMT CP CP UNP CSX UTX NSC

 
Norfolk Southern (NSC) Stock Up 25% in 9 Months: Here's Why

2018-10-02 zacks
Stocks in the railroad space are being aided by a buoyant U.S. economy. Also, a robust domestic economy is leading increased transportation of goods across the country.
CP CP UNP CSX NSC

45
Lanny's September Dividend Income Summary

2018-10-02 seekingalpha
The quarter-end baby! We all look and wait for a big dividend income month and September usually never fails. The leaves are changing colors, the temperature is dropping and I have a sweatshirt on. Sitting here with a nice cup of joe and looking at the dividend income that flowed into my account. Blessed beyond belief everyone. Now let's grab that cup of coffee and see my September dividend income results!
LMT BLT D BHPBF DWDP NSC MAT ISBA MYBF BHP KHC BBL BHP BHPLF DAL MCD

158
CSX's Elixir

2018-10-02 seekingalpha
CSX remains a market darling through the end of the third quarter, up 35% for the period.
X TSNU GEC KBH GE GIS RAD GNE HOG TSN NSC

 
Kansas City Southern Still Hasn't Arrived

2018-09-26 seekingalpha
I think the market remains too optimistic about the prospects for Kansas City Southern. This is remarkable in light of the deteriorating operating ratio from last year to this one.
CSX NSC KSU

2
Southwest Airlines (LUV) Gains 21% in 3 Months: Here's Why

2018-09-25 zacks
Shares of Southwest Airlines Co. (LUV - Free Report) have gained 21% in the past three months, outperforming its industry's 3.8% growth.
ARCB TRN NSC

2
Golar LNG Rallies 27% In A Year: What's Driving the Stock?

2018-09-25 zacks
Despite high operating expenses, shares of Golar LNG Limited (GLNG - Free Report) have fared well in a year’s time. The stock has gained 27.5%, against the industry’s decline of 6%.
ARCB GLNG TRN NSC

5
LATAM Airlines (LTM) Stock Down 29% Year to Date: Here's Why

2018-09-24 zacks
Shares of LATAM Airlines Group S.A. (LTM - Free Report) have lost 29.4% of their value so far this year compared with the Zacks Airline industry’s 11.1% decline.
ODFL KBH SKYW ODLF NSC

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to NSC / Norfolk Southern Corp. on message board site Silicon Investor.

Ensco International Inc. (ESV) Ensco International Inc. (ESV) Ensco International Inc. (ESV) SliderOnTheBlack - Trading Guru or Unscrupulous Villain? SliderOnTheBlack - Trading Guru or Unscrupulous Villain? SliderOnTheBlack - Trading Guru or Unscrupulous Villain?
US vs Amr Elgindy - Trial Transcripts US vs Amr Elgindy - Trial Transcripts US vs Amr Elgindy - Trial Transcripts MSFT Internet Explorer vs. NSCP Navigator MSFT Internet Explorer vs. NSCP Navigator MSFT Internet Explorer vs. NSCP Navigator
Nuinsco Resources Nuinsco Resources Nuinsco Resources Silver Standard Resources Inc. NSC: SSRI CVE: SSO Silver Standard Resources Inc. NSC: SSRI CVE: SSO Silver Standard Resources Inc. NSC: SSRI CVE: SSO
Nuinsco Resources (NWI) Nuinsco Resources (NWI) Nuinsco Resources (NWI) Conscience Zero=Bush Supporter Conscience Zero=Bush Supporter Conscience Zero=Bush Supporter
transcanada pipelines (TRP) transcanada pipelines (TRP) transcanada pipelines (TRP) Genaissance Pharmaceuticals (GNSC) Genaissance Pharmaceuticals (GNSC) Genaissance Pharmaceuticals (GNSC)
CUSIP: 655844108